Biotech entity
Every one of those 1 sits in a single category, clinical-trial. Of the tracked stories, 1 of 1 also mention Boston Children's Hospital, the most common co-covered peer. Peanut allergy appears in 1 tracked Biotech story from August 24, 2026.
Last mentioned: 16h ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, clinical-trial. Of the tracked stories, 1 of 1 also mention Boston Children's Hospital, the most common co-covered peer. Peanut allergy appears in 1 tracked Biotech story from August 24, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 6 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Peanut allergy. Shared-story counts are live from our verified record — not editorial picks.
A small Science Translational Medicine trial at Boston Children's Hospital provides first human evidence that donor microbiota can improve peanut allergy, revealing gut bacteria-metabolite-immune interactions. The study opens a new microbiome-based therapeutic pathway but requires larger confirmatory trials.
Source: fox5ny.com · fox26houston.com
Peanut allergy is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
